Clinical Trials Arena on MSN2d
Immunovant will not seek approval for MG therapy, despite hitting endpointsThe company plans to use results from its Phase III myasthenia gravis study to support its pipeline candidate IMVT-1402 over ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback